[The use of terazosin hydrochloride (Hytrin) in the treatment of patients with benign prostatic hyperplasia].
Sivkov
A V
AV
Apolikhin
O I
OI
Medvedev
A A
AA
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin